Insmed Incorporated (NASDAQ:INSM) Insider Sells $95,108.48 in Stock

Insmed Incorporated (NASDAQ:INSM) insider Martina M.D. Flammer sold 1,384 shares of the company’s stock in a transaction that occurred on Tuesday, January 14th. The stock was sold at an average price of $68.72, for a total value of $95,108.48. Following the completion of the sale, the insider now owns 100,165 shares in the company, valued at $6,883,338.80. The trade was a 1.36 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Martina M.D. Flammer also recently made the following trade(s):

• On Friday, January 10th, Martina M.D. Flammer sold 6,172 shares of Insmed stock. The stock was sold at an average price of $63.64, for a total value of $392,786.08.
• On Tuesday, January 7th, Martina M.D. Flammer sold 3,344 shares of Insmed stock. The shares were sold at an average price of $65.91, for a total value of $220,403.04.

Insmed Stock Performance

Shares of INSM traded up $2.55 on Thursday, reaching $72.75. The company’s stock had a trading volume of 2,264,024 shares, compared to its average volume of 2,139,833. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $80.53. The stock’s 50 day simple moving average is $71.18 and its two-hundred day simple moving average is $72.47. The stock has a market capitalization of $13.01 billion, a P/E ratio of -13.11 and a beta of 1.12. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The firm had revenue of $93.40 million during the quarter, compared to analysts’ expectations of $93.36 million. The firm’s revenue for the quarter was up 18.1% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.10) earnings per share. Research analysts forecast that Insmed Incorporated will post -5.44 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Insmed

Hedge funds have recently modified their holdings of the company. Capital CS Group LLC purchased a new position in shares of Insmed in the fourth quarter worth $586,000. Orion Portfolio Solutions LLC increased its holdings in Insmed by 48.5% in the 3rd quarter. Orion Portfolio Solutions LLC now owns 28,087 shares of the biopharmaceutical company’s stock valued at $2,050,000 after acquiring an additional 9,170 shares during the last quarter. Ally Bridge Group NY LLC lifted its stake in Insmed by 16.9% in the 3rd quarter. Ally Bridge Group NY LLC now owns 150,833 shares of the biopharmaceutical company’s stock worth $11,011,000 after purchasing an additional 21,833 shares in the last quarter. Vestal Point Capital LP boosted its holdings in shares of Insmed by 113.3% during the 3rd quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company’s stock valued at $116,800,000 after purchasing an additional 850,000 shares during the last quarter. Finally, TimesSquare Capital Management LLC purchased a new position in shares of Insmed during the third quarter valued at about $35,322,000.

Wall Street Analyst Weigh In

Several research analysts have issued reports on INSM shares. JPMorgan Chase & Co. lifted their target price on shares of Insmed from $74.00 to $83.00 and gave the stock an “overweight” rating in a report on Friday, November 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $90.00 price objective on shares of Insmed in a research report on Friday, November 1st. Truist Financial reissued a “buy” rating and issued a $105.00 target price (up previously from $100.00) on shares of Insmed in a report on Friday, November 1st. Finally, Bank of America upped their price target on Insmed from $84.00 to $86.00 and gave the company a “buy” rating in a report on Wednesday, October 9th. One investment analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat, Insmed has a consensus rating of “Moderate Buy” and a consensus target price of $83.67.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.